A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Dec 2017
At a glance
- Drugs Benralizumab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms TERRANOVA
- Sponsors AstraZeneca
- 29 May 2017 Planned End Date changed from 1 Apr 2018 to 9 Apr 2018.
- 29 May 2017 Planned primary completion date changed from 1 Apr 2018 to 9 Apr 2018.
- 08 Feb 2017 Status changed from recruiting to active, no longer recruiting.